TABLE 2.

In vitro susceptibilities to fluconazole and itraconazole of BSI isolates of various species of Candida from 1997 and 1998

Species	Yr	No. of isolates	Antifungal agent	MIC (μg/ml)a			% Rb
				Range	50%	90%
C. albicans	1997c	163	Fluconazole	0.12–>128	0.25	1.0	0.6
			Itraconazole	0.015–>8.0	0.06	0.12	0.6
	1998	181	Fluconazole	0.12–>128	0.25	0.5	1.1
			Itraconazole	0.008–>8.0	0.03	0.12	2.2
C. glabrata	1997c	46	Fluconazole	1.0–>128	8.0	32	8.7
			Itraconazole	0.12–>8.0	0.5	2.0	36.9
	1998	58	Fluconazole	0.25–128	8.0	16	5.2
			Itraconazole	0.06–>8.0	0.5	2.0	32.8
C. parapsilosis	1997c	48	Fluconazole	0.12–4.0	1.0	2.0	0
			Itraconazole	0.015–0.5	0.12	0.25	0
	1998	47	Fluconazole	0.25–4.0	0.5	1.0	0
			Itraconazole	0.015–0.5	0.06	0.25	0
C. tropicalis	1997c	24	Fluconazole	0.25–4.0	0.5	2.0	0
			Itraconazole	0.03–1.0	0.12	0.5	4.2
	1998	28	Fluconazole	0.25–8.0	0.5	1.0	0
			Itraconazole	0.015–1.0	0.06	0.5	3.6
C. krusei	1997c	6	Fluconazole	32–64	32		100
			Itraconazole	0.12–2.0	1.0		66.6
	1998	4	Fluconazole	8.0–32	32		100d
			Itraconazole	0.12–0.5	0.25		0

^a50% and 90%, MICs for 50 and 90% of isolates tested, respectively. 

^b% R, percent resistant as determined by using interpretive breakpoint criteria of the NCCLS (13): fluconazole resistance, ≥64 μg/ml; itraconazole resistance, ≥1.0 μg/ml. 

^cAdapted from the work of Pfaller et al. (20). 

^dIsolates of C. krusei are considered resistant to fluconazole, regardless of the MIC.